Abstract: The present invention relates to a composition for percutaneous administration which can enhance percutaneous absorption of a physiologically active ingredient and a method of enhancing percutaneous absorption of a physiologically active ingredient employing the same.

Abstract: Disclosed is a method of treating a skin lesion comprising applying to the lesion a dry bandage comprising a gas- and moisture-permeable, flexible, thermoplastic film impregnated with a pharmaceutical.

Abstract: A magnesium aluminometasilicate coated composite powder which comprises magnesium aluminometasilicate, or magnesium aluminometasilicate and at least one other powder coated on a surface of a core powder and which is usable in, for example, a skin treatment agent, decodorant, and oral composition.

Abstract: The present invention relates to a transdermal system with graduated drug release and to its use for the local or systemic dermal drug administration in human and veterinary medicine, or in cosmetics.

Abstract: A medical adhesive comprising a plaster layer containing the following ingredients, characterized in that the ingredient 2 is incorporated in a larger amount than the ingredient 5 and in an amount not less than 25% by weight relative to the total amount of the ingredients 1.about.5, and the plaster layer is a W/O type:1 a medicinal ingredient,2 a hydrophobic polymer having a glass transition temperature (Tg) of -65.degree. C. to 35.degree. C.3 a percutaneous absorption-promoting agent,4 water, and5 a hydrophilic polymer which is soluble or capable of swelling in water; anda medical adhesive which comprises a porous base layer in the plaster layer or in contact with the plaster layer, which enable stable release of the medicinal ingredient, the percutaneous absorption-promoting agents and so on and sustaining of the pharmacological effects over a long period.

Abstract: A topical composition containing a dissolved drug or the like (e.g. hydrocortisone acetate) preferably in saturated solution, and a solubilizer (e.g. propylene glycol), and preferably water and an antinucleant, is applied to a water-wetted area of the body, such as the hair or scalp, such that, on mixing with the body water, the resultant drug concentration exceeds the saturated drug solubility in the initially formed resultant mixture, thus giving a supersaturated drug composition.

Abstract: A delivery system is disclosed for delivering a beneficial agent to an animal. The delivery system comprises a wall that surrounds a lumen, said wall comprising a composition that limits the passage of fluid into the system and a composition that permits the passage of fluid into the system. The lumen comprises a beneficial agent and an expandable member. The delivery system comprises an exit means for delivering the beneficial agent.

Abstract: The present invention concerns a vanadyl organo-mineral compound which is in the form of a complex of vanadyl and of cystein, having the following general formula: ##STR1## wherein, either x is 1 and y is 0, or x is 0 and y is 1, and wherein n, p and m are respectively integers with a value of 1 or 2.

Abstract: The agents for the treatment of conditions of severe pain, and especially of tumor pain and post-operative pain, consist of soft gelatin capsules containing from about 30 to about 50 parts by weight of ibuprofen and from about 1.5 to about 4 parts by weight of codeine and/or physiologically compatible salts thereof, partially dissolved and partially suspended in about 68.5 to about 46 parts by weight of polyoxyethylene-polyoxypropylene-diol or in a mixture comprising about 30 to about 76 parts by weight of polyoxyethylene-polyoxypropylene- diol or polyethylene-glycol or polypropyleneglycol and from about 7 to about 40 parts by weight of a physiologically compatible surfactant.

Abstract: A method of preventing sensitization in transdermal drug delivery by the inclusion of a corticosteroid, which will be co-extensively coadministered with the sensitizing agent.

Abstract: The invention provides a solid pharmaceutical dosage form comprising:(i) cimetidine; and(ii) antacid, wherein at least part of the antacid is in the form of granules comprising a freely water-soluble solid diluent, the antacid, and a rapidly swellable water-insoluble disintegrant.Compositions of this type overcome the problem of the reduced bioavailability of cimetidine which can occur when cimetidine is co-administered with antacids.

Abstract: Apparatus and method for repairing semiconductor masks and reticles is disclosed, utilizing a focused ion beam system capable of delivering, from a single ion beam column, several different species of focused ion beams, each of which is individually optimized to meet the differing requirements of the major functions to be performed in mask repair. This method allows the mask to be imaged with high resolution and minimum mask damage. Opaque defects are removed by sputter etching at high rates with minimum damage to the mask substrate, and clear defects are filled in at high rates directly from the beam by deposition of a metallic or other substance compatible with the mask materials. A focused ion beam column able to produce precisely focused ion beams is employed and is operated at high energies for imaging and sputter etching, and at low energies for imaging and deposition. A liquid metal alloy source containing suitable atomic species is employed.

Abstract: Transdermal administration of hydrophobic drugs via a diffusion mechanism in which the drug is dissolved in a carrier at concentrations that are 20% to 80% of the saturation concentration. The flux of drug from the device is non-Fickian and is substantially greater than the flux observed when the drug is at saturation.

Abstract: A patch for the transdermal delivery of pharmaceutical drugs. The patch is characterized by having a single mass of elastomer in which the active drug and a percutaneous absorption enhancer are homogeneously dispersed throughout. The patch is especially well suited to delivering the beta.sub.2 adrenergic agonist drug albuterol.

Abstract: Disclosed is a drug-releaser comprising a porous body of biocompatibility filled with a medicine. Specifically, such porous body is made of baked calcium phosphate, 2-hydroxyethylmethacrylate, chitin, chitosan or their delivatives. Implantation or artery-injection of such drug-releaser causes a discernible curing effect on affected parts of the living body without causing any irritativeness. The steady release of the medicine from HAP particles to affected parts and the blockade of surrounding capillary vessels leading to such affected parts causes a remarkable tumor inhibitory effect.

Abstract: A dosage form is disclosed comprising a coat that surrounds a drug. The coat comprises a subcoat and an overcoat thermally annealed to provide a single unit coat around the drug.

Abstract: The present invention provides a method of reducing or preventing skin irritation of a weak base drug by inhibiting the accumulation of the drug in the lysosomes. The drug is irritating to humans, i.e., the drug is susceptible to inducing skin or mucosa irritation in a human when the drug is transdermally administered to the human at a therapeutically effective rate. Irritation reduction or prevention is induced by coadministering to the skin or mucosa of the human:(a) a therapeutically effective amount of a weak base drug which is irritating to humans, at a therapeutically effective rate over a predetermined period of time; and(b) an effective amount of an agent capable of inhibiting the lysosomal uptake of the drug to reduce or prevent irritation to the skin or mucosa.

Abstract: A percutaneous drug delivery system, method, and kit are disclosed. The method comprises applying an enzyme preparation to a localized area of skin for a predetermined amount of time to enhance that area of skin's permeability to selected drugs, occluding the area of skin during the application, and then applying the selected drug(s) to the area of skin to allow the drug to penetrate through the skin and into the circulatory system of the animal. Greatly enhanced penetration of chemicals through the skin results from the enzyme treatment.

Abstract: A dosage form is disclosed that comprises means inside the dosage form for providing a substantially drug-free interval before the dosage form delivers a drug from inside the dosage form. The dosage form in an embodiment comprises a drug on the exterior of the dosage form, which drug is available for immediate delivery.

Abstract: An adhesive assembly is provided having a temperature-sensitive adhesive composition coated on the surface of a selected substrate. The adhesive composition is nontacky or slightly tacky at room temperature, but is aggressively tacky at skin temperature. The assemblies include adhesive tapes, bandages, films and the like.